Jordan Silverstein
Investor Relations Kontakt bei IMMATICS N.V.
Vermögen: 2 Mio $ am 30.04.2024
Ursprung des Netzwerks ersten Grades von Jordan Silverstein
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
| Public Company | Biotechnology | 24 | |
| Subsidiary | Medical Specialties | 24 | |
12
| Public Company | Biotechnology | 12 |
The Golf Championships, Inc.
2
| Subsidiary | 2 | |
MacroChem Corp.
 MacroChem Corp. Pharmaceuticals: MajorHealth Technology MacroChem Corp. Develops pharmaceutical products to prevent chemicals in insect repellant from penetrating the skin. Its drug delivery technologies include Soft Enhancement of Percutaneous Absorption, MacroDem and DermaPass. The company was founded in 1982 and is located in Wellesley Hills, MI.
2
| Subsidiary | Pharmaceuticals: Major | 2 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Jordan Silverstein
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
Immatics Biotechnologies GmbH
 Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Pharmaceuticals: Major | Chairman Director/Board Member Chief Executive Officer Founder Director of Finance/CFO Director/Board Member Corporate Officer/Principal Chief Tech/Sci/R&D Officer Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
Immatics US, Inc.
 Immatics US, Inc. BiotechnologyHealth Technology Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX. | Biotechnology | Chairman Director/Board Member Director/Board Member Chief Executive Officer Founder Director/Board Member Director/Board Member Founder Chief Tech/Sci/R&D Officer | |
| GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
dievini Hopp BioTech holding GmbH & Co. KG
 dievini Hopp BioTech holding GmbH & Co. KG Investment ManagersFinance dievini Hopp BioTech holding GmbH & Co. KG operates as a private investment and consulting firm. It invests in companies related to the life and health sciences. It focuses with companies that diagnoses and provides therapy in the fields of oncology, neurology, infectious diseases, cell therapy and drug delivery systems. The company is headquartered in Walldorf, Germany. | Investment Managers | Private Equity Investor Founder Chief Executive Officer | |
Newcleo Ltd.
 Newcleo Ltd. Electrical ProductsProducer Manufacturing Newcleo Ltd. is a British company that is disrupting the nuclear energy industry to play its part in climate change mitigation and decarbonization. Newcleo is based in an undisclosed location. The company is focused on reducing the environmental impact of nuclear fission and providing safe and clean energy to meet the growing energy needs. Newcleo has announced an agreement to purchase the outstanding shares of the Rütschi Group for a consideration of EUR 68.9 million. The company is planning ahead to work together with potential local, regional, and international suppliers to maximize the opportunities that Newcleo can bring. The company was founded in 2021 by Elisabeth Rizzotti and Stefano Buono, who has been the CEO since 2021. | Electrical Products | Director/Board Member Chief Executive Officer Director/Board Member | |
| AC IMMUNE SA | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
Molecular Health, Inc.
 Molecular Health, Inc. Packaged SoftwareTechnology Services Molecular Health, Inc. operates as a cloud-based healthcare decision support technology to enable evidence-based treatment decisions. The company was founded in 2004 and is headquartered in Boston, MA. | Packaged Software | Chairman Director/Board Member Director/Board Member | |
| Eberhard Karls Universität Tübingen | College/University | Doctorate Degree Doctorate Degree Doctorate Degree | |
CureVac SE
 CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
| dievini Verwaltungs GmbH | Chief Executive Officer Chief Executive Officer Chief Executive Officer | ||
| HEIDELBERG PHARMA AG | Pharmaceuticals: Major | Director/Board Member Chairman Director/Board Member | |
Molecular Health GmbH
 Molecular Health GmbH Miscellaneous Commercial ServicesCommercial Services Part of Posbelduf Biotech AG, Molecular Health GmbH is a German management consulting company. The company is based in Heidelberg, Germany. The company was founded in 2004 by Friedrich von Bohlen und Halbach. Friedrich von Bohlen und Halbach has been the CEO since 2004. | Miscellaneous Commercial Services | Chief Executive Officer Chairman Director/Board Member | |
Amgen Rockville, Inc.
 Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | Biotechnology | Director/Board Member Chief Tech/Sci/R&D Officer | |
| Sciences Po | College/University | Undergraduate Degree Undergraduate Degree | |
| Rutgers State University of New Jersey | College/University | Undergraduate Degree Doctorate Degree | |
| University of Bocconi | College/University | Undergraduate Degree Undergraduate Degree | |
| CUREVAC N.V. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| PHILOGEN S.P.A. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| FRESENIUS SE & CO. KGAA | Medical Specialties | Corporate Officer/Principal Corporate Officer/Principal | |
| Massachusetts Institute of Technology | College/University | Doctorate Degree Undergraduate Degree | |
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| Ludwig-Maximilians-Universität München | College/University | Doctorate Degree Undergraduate Degree | |
Apogenix AG
 Apogenix AG BiotechnologyHealth Technology Apogenix AG develops immuno-oncology therapeutics for the treatment of cancer and malignant diseases. It offers protein-based therapeutics, including APG101, a human soluble fusion protein combining the extracellular domain of the CD95-receptor and the Fc part blocking CD95L-mediated signaling pathways; and IL-4 blocker that prevents over expression of anti-apoptotic proteins cells. The firm offers its drugs for malignant and inflammatory diseases. The company was founded by Peter Heinrich Krammer and Henning Walczak in 2005 and is headquartered in Heidelberg, Germany. | Biotechnology | Chairman Director/Board Member | |
Novaliq GmbH
 Novaliq GmbH Medical SpecialtiesHealth Technology Novaliq GmbH develops and markets drug delivery systems. The firm specializes in the development of novel pharmaceutical formulations based on semifluorinated alkanes . It product pipeline encompasses the NovaTears, CyckAol, and I-Let Protect technologies. The company was founded in 2004 and is headquartered in Heidelberg, Germany. | Medical Specialties | Chairman Director/Board Member | |
febit holding GmbH
 febit holding GmbH Medical/Nursing ServicesHealth Services febit holding GmbH engages in the design and development of technologies used for DNA analysis. It specializes in technologies with applications in genomic research, RNA expression profiling, and other diagnostic and molecular biology fields. The company was founded by Markus Beier, Ramon Gueimil, Peer F. Staehler, Matthias Scheffler, and Cord F. Stähler in 2005 and is headquartered in Heidelberg, Germany. | Medical/Nursing Services | Director/Board Member Chairman | |
| 2INVEST AG | Financial Conglomerates | Director/Board Member Director/Board Member | |
| IMMUNOCORE HOLDINGS PLC | Biotechnology | Chief Executive Officer Director/Board Member | |
| Febit, Inc. | Director/Board Member Chairman | ||
Lantheus Medical Imaging, Inc.
 Lantheus Medical Imaging, Inc. Medical SpecialtiesHealth Technology Lantheus Medical Imaging, Inc. engages in the manufacture, marketing, sale, and distribution of medical imaging products. It provides diagnostic imaging and nuclear medicine products that assist clinicians with the detection of disease, primarily cardiovascular. Its product protfolio includes DEFINITY, TechneLite, Xenon, AZEDRA, Cardiolite, and NEUROLITE. The company was founded in 1956 and is headquartered in North Billerica, MA. | Medical Specialties | Director/Board Member Director/Board Member | |
| Université Paris 1 Panthéon-Sorbonne | College/University | Graduate Degree Graduate Degree | |
American Society of Clinical Oncology, Inc.
 American Society of Clinical Oncology, Inc. Medical/Nursing ServicesHealth Services The American Society of Clinical Oncology is a non-profit organization founded in 1964 with the overarching goals of improving cancer care and prevention. More than 27,000 oncology practitioners belong to ASCO, representing all oncology disciplines and subspecialties. Members include physicians and health-care professionals in all levels of the practice of oncology. American Society of Clinical Oncology is the world’s leading professional organization representing physicians who treat people with cancer. ASCO’s members set the standard for patient care worldwide and lead the way in carrying out clinical research aimed at improving the prevention, diagnosis, and treatment of cancer. ASCO's efforts are also directed toward advocating for policies that provide access to high-quality care for all patients with cancer and at supporting the increased funding for clinical and translational research. | Medical/Nursing Services | Corporate Officer/Principal Corporate Officer/Principal | |
| University of Freiburg | College/University | Graduate Degree Undergraduate Degree | |
| Yale University | College/University | Doctorate Degree Undergraduate Degree | |
| NOVARTIS AG | Pharmaceuticals: Major | Investor Relations Contact Corporate Officer/Principal | |
| IVERIC BIO, INC. | Pharmaceuticals: Generic | Director of Finance/CFO Corporate Officer/Principal | |
| MORPHOSYS AG | Biotechnology | Corporate Officer/Principal Director of Finance/CFO | |
| VIVORYON THERAPEUTICS N.V. | Biotechnology | Director of Finance/CFO Director of Finance/CFO | |
PROMETHERA Biosciences SA
 PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | Pharmaceuticals: Major | Director/Board Member Chairman | |
| The University of Chicago | College/University | Masters Business Admin Undergraduate Degree | |
| MEDIGENE AG | Biotechnology | Chief Executive Officer Director of Finance/CFO | |
| ABEONA THERAPEUTICS INC. | Pharmaceuticals: Major | Director/Board Member General Counsel | |
| NPS PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Executive Officer General Counsel | |
InflaRx GmbH
 InflaRx GmbH BiotechnologyHealth Technology InflaRx GmbH operates as a biotech company which develops new therapeutics in the field of inflammation. It focuses on the general area of inflammation including indications such as SIRS and SEPSIS by applying innovative therapeutics in order to prevent organ dysfunction or limit progression into organ failure. The firm's complement system is activated and produces large amounts of products including complement 5a (C5a), C3a, C4a and membrane-attack complex (MAC). The company was founded in 2007 by Niels Riedemann and Renfeng Guo and is headquartered in Jena, Germany. | Biotechnology | Director/Board Member Director/Board Member | |
| LANTHEUS HOLDINGS, INC. | Medical Specialties | Director/Board Member Director/Board Member | |
Advanced Accelerator Applications (UK & Ireland) Ltd.
 Advanced Accelerator Applications (UK & Ireland) Ltd. Medical SpecialtiesHealth Technology Imaging Equipment Ltd. distributes medical technologies. The firm offers PET and nuclear medical, imaging equipment, radiotherapy products, diagnostic imaging, radiation safety quality assurance, medical phantoms, ultrasound quality assurance products, molecular imaging, radiology tables, and bone densitometry products for the purpose of diagnosing osteoporosis. The company was founded in 2001 and is headquartered in Somerset, the United Kingdom. | Medical Specialties | Director/Board Member Director/Board Member |
Statistik
International
| Deutschland | 25 |
| Vereinigte Staaten | 16 |
| Vereinigtes Königreich | 5 |
| Schweiz | 3 |
| Frankreich | 3 |
Sektoral
| Health Technology | 30 |
| Consumer Services | 10 |
| Finance | 4 |
| Commercial Services | 4 |
| Health Services | 3 |
Operativ
| Director/Board Member | 287 |
| Corporate Officer/Principal | 128 |
| Independent Dir/Board Member | 84 |
| Chairman | 84 |
| Chief Executive Officer | 70 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Christof Hettich | 40 |
| Kapil Dhingra | 39 |
| Claudio Costamagna | 38 |
| Friedrich von Bohlen und Halbach | 36 |
| Eliot Forster | 35 |
| Francois Nader | 28 |
| Raffaele Petrone | 27 |
| Peter Chambré | 23 |
| Leopoldo Giampaolo Zambeletti | 22 |
| Mathias Hothum | 19 |
| Adam Stone | 17 |
| Michael Atieh | 16 |
| Carsten Reinhardt | 16 |
| Thomas Taapken | 16 |
| Yvonne Greenstreet | 15 |
- Börse
- Insiders
- Jordan Silverstein
- Unternehmensverbindungen
